Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement

Neuromodulation

Volumn 14, Issue 1, 2011, Pages 38-45

  Schiess, Mya C ^a   Oh, Irene J ^a   Stimming, Erin F ^a   Lucke, Joseph ^b   Acosta, Fernando ^c   Fisher, Stanley ^d   Simpson, Richard K ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Cook Children's Hospital ^*  (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Baclofen; functional independence; hemiparesis; intrathecal; quality of life; spasticity

Indexed keywords

BACLOFEN; DIAZEPAM; TIZANIDINE;

ADULT; AGED; ARM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FAMILY; FEMALE; FUNCTIONAL INDEPENDENCE MEASURE; GAIT; HEMIPARESIS; HUMAN; LEG; MALE; MANUAL MUSCLE TEST; MODIFIED ASHWORTH SCALE; MOTOR CONTROL; MOTOR PERFORMANCE; MOVEMENT (PHYSIOLOGY); NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; PERSONALITY; POSTSTROKE SPASTIC HEMIPARESIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; SELF CARE; SOCIAL CARE; STROKE; STROKE PATIENT; STROKE SPECIFIC QUALITY OF LIFE SCALE; TREATMENT DURATION; UPPER EXTREMITY MANUAL ACTIVITY LOG; WALKING SPEED;

EID: 79251553731     PISSN: 10947159     EISSN: 15251403     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2010.00308.x     Document Type: Article

References (33)

1. Grysiewicz RA, Thomas K, Pandey DK,. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality and risk factors. Neurol Clin 2008; 26: 871-895.
2. Harris JE, Eng JJ,. Paretic upper-limb strength best explains arm activity in people with stroke. Phys Ther 2007; 87: 88-97.
3. Francisco GE, Yablon SA, Schiess MC, Wiggs L, Cavalier S, Grissom S,. Consensus panel guidelines for the use of intrathecal baclofen therapy in post stroke spastic hypertonia. Top Stroke Rehabil 2006; 13: 74-85.
4. O'Dwyer NJ, Ada L, Neilson PD,. Spasticity and muscle contracture following stroke. Brain 1996; 119: 1737-1749.
5. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN,. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001; 32: 2099-2109.
6. Francisco GE,. Intrathecal baclofen therapy for stroke related spasticity. Top Stroke Rehabil 2001; 8: 36-46.
7. Francisco GE, Boake C,. Improvement in walking speed in post stroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil 2003; 84: 1194-1199.
8. Lance JW,. Symposium synopsis. In:, Feldman FG, Young RR, Koella WP, eds. Spasticity: disorder of motor control. Chicago, IL: Year Book Medical, 1980: 480-494.
9. Twitchell TE,. The restoration of motor function following hemiplegia in man. Brain 1951; 74: 443-480.
10. Ward NS, Brown MM, Thompson AJ, Frackowiak RSJ,. Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain 2003; 126: 1-21.
11. Yagura H, Miyai I, Seike Y, Suzuki T, Yanagibara T,. Benefit of inpatient multidisciplinary rehabilitation up to 1 year after stroke. Arch Phys Med Rehabil 2003; 84: 1687-1691.
12. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK,. Prevalence of spasticity post-stroke. Clin Rehabil 2002; 16: 515-522.
13. Sommerfield DK, Eek EU-B, Svensson A-K, Holmqvist LW, von Arbin MH,. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35: 134-140.
14. O'Brien CF, Seeberger LC, Smith DB,. Spasticity after stroke: epidemiology and optimal treatment. Drugs Aging 1996; 9: 332-340.
15. Gallichio JE,. Pharmacological management of spasticity following stroke. Phys Ther 2004; 84: 973-981.
16. Stempien L, Tsai T,. Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 2000; 79: 536-541.
17. Sampson F, Hayward A, Evans G, Morton R, Collett B,. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J Neurosurg 2002; 96: 1052-1057.
18. Meythaler JM, Guin-Renfroe S, Hadley MN,. Continually infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Am J Phys Med Rehabil 1999; 78: 247-254.
19. Remy-Neris O, Tiffeau V, Bouilland S, Bussel B,. Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the anti-spastic effect during gait. Arch Phys Med Rehabil 2003; 84: 643-650.
20. Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom P,. Intrathecal Baclofen management of post stroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 2006; 87: 1509-1515.
21. Kofler M, Quirbach E, Schauer R, Singer M, Saltuari L,. Limitations of intrathecal baclofen for spastic hemiparesis following stroke. Neurorehabil Neural Repair 2009; 26-31.
22. Ashworth B,. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-542.
23. Bohannon RW, Smith MB,. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207.
24. Blackburn M, van Vliet P, Modkett SP,. Reliability of measurements obtained with the Modified Ashworth Scale in the lower extremities of people with stroke. Phys Ther 2002; 82: 25-34.
25. O'Brien MD,. Aids to the examination of the peripheral nervous system. St. Louis, MO: WB Saunders, 4th edition prepared for the Guarantors of Brain 1999-2000, 2000.
26. Mendell JR, Florence JM,. Manual muscle testing. Muscle Nerve 1990; 13: S16-S20.
27. Stineman MG, Shea JA, Jette A, et al. The Functional Independence Measure: tests of scaling assumptions, structure, and reliability across 20 diverse impairment categories. Arch Phys Med Rehabil 1996; 77: 1101-1108.
28. Oczkowski W, Barreca S,. The Functional Independence Measure: its use to identify rehabilitation needs in stroke survivors. Arch Phys Med Rehabil 1993; 74: 1291-1294.
29. Williams L, Weinberger M, Harris L, Clark D, BiIIer J,. Development of a stroke specific quality of life scale. Stroke 1999; 30: 1362-1369.
30. Uswatte G, Taub E, Morris DM, Vignolo M, McCullough K,. Reliability and validity of the upper-extremity Motor Activity Log-14 for measuring real-world are use. Stroke 2005; 36: 2496-2499.
31. Grabb PA, Guin-Renfroe S, Meythaler JM,. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery 1999; 45: 833-837.
32. Chappuis DM, Boortz-Marx RL, Stuckey MW, Spiewak KK, DesLauriers LM, Baxter TL,. Safety of continuously infused intrathecal baclofen in the cervical and high thoracic areas for patients with spasticity, dystonia, and movement disorders: a prospective case series. Arch Phys Med Rehabil 2002; 83: 7676.
33. Hintze JL,. NCSS descriptive statistics, means, quality control, design of experiments. pub NCSS JL Hintze, Kaysville, Utah, User's Guide Book II & NCSS software, 2006.